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Lymph node (LN) stromal cells, particularly fibroblastic reticular cells (FRCs), 2 
provide critical structural support and regulate immunity, tolerance and 3 
transport properties of LNs. In many tumors, LN metastasis is predictive of 4 
poor prognosis. However, stromal contribution to the evolving 5 
microenvironment of tumor draining LNs (TDLN) remains poorly understood. 6 
Here we show that FRCs of TDLNs expand but also significantly remodel. 7 
Comparative transcriptional analysis of resting and TDLN FRCs demonstrated 8 
reprogramming of key pathways including matrix remodeling, 9 
chemokine/cytokine signaling and immune functions including leukocyte 10 
recruitment, migration and activation. Stromal-mediated structural and 11 
transcriptional adaptations, including downregulation of CCL21 and IL7, were 12 
accompanied by altered cellular composition and aberrant localization, both 13 
characteristics typical of immune dysfunction and the generation of a 14 
suppressive niche. 15 
 16 
INTRODUCTION 17 
LNs form an integral part of both our lymphatic and immune systems, acting 18 
as “filters” to surveil potential lymph borne pathogens, and as an 19 
immunological hub maintaining homeostasis or eliciting effective immune 20 
responses.  To enable these specialized functions, the LN is highly organized 21 
into discrete cellular compartments. The supporting stromal cells are central 22 
to organization and function1, 2, 3 and the major stromal subsets, lymphatic 23 
endothelial cells (LEC), blood endothelial cells (BEC) and fibroblastic reticular 24 
cells (FRC) can be distinguished by their relative expression of surface 25 
markers podoplanin and CD312. 26 
 27 
Lymph draining from peripheral tissues enters via LEC-lined afferent 28 
lymphatic vessels and along lymphatics that line the subcapsular and 29 
medullary sinuses before exiting in efferent lymphatics4.  However, smaller 30 
constituents such as chemokines and soluble antigen below 70kDa can cross 31 
the lymphatic sinus floor and penetrate deeper into the LN, along narrow 32 
conduit channels formed by collagen fibrils and FRCs5, 6, 7. While the conduit 33 
 3 
network provides underlying structural support4, FRCs have additional 1 
properties vital for proper lymph node function. They produce a number of 2 
chemical cues that are critical for immune cell migration, localization and 3 
survival such as homeostatic chemokines CCL19 and 218, whose receptor 4 
CCR7 is present on naïve T cells, B cells and Dendritic Cells (DCs)9. 5 
Gradients of these chemokines direct intranodal migration and survival during 6 
homeostasis and infection3, 10, 11, lymphocyte homing to LNs12 and mediate 7 
interactions between T cells and DCs8. FRCs are a major source of IL7, 8 
essential for naïve T cell survival2. Those resident in follicles also contribute to 9 
B cell homeostasis and follicle identity via the production of the cytokine 10 
BAFF13. Moreover, specific destruction of FRCs is a method employed by 11 
viruses to avoid detection during infection14. More recently, evidence indicates 12 
that FRCs not only contribute to the onset of effective immune responses, but 13 
conversely to immunological tolerance, switching off an immune response via 14 
deletion of self-reactive T cells15, 16, 17. 15 
 16 
LNs also feature in numerous pathologies. In cancer, they represent the first 17 
site of metastasis for many tumor types and are independently predictive of 18 
poor prognosis18, 19. Yet, despite our increasing efforts to understand the 19 
processes of lymphatic metastasis and LN colonization20, the mechanisms 20 
underlying the failure of effective anti-tumor immune responses in the LN, and 21 
the relationship of both to poor outcome remain poorly characterized. Tumor-22 
derived interstitial fluid and its constituents drain to downstream LNs, bathing 23 
the cells it encounters en route. Therefore, the potential exists for tumors to 24 
exploit this means of communication to remotely control responses in tissues 25 
such as the LN to its survival advantage. 26 
 27 
Given our current knowledge pertaining to stromal cell contribution in LN 28 
function, and the importance of stromal cells within the tumor 29 
microenvironment, we characterized the response and potential 30 
consequences of changes to FRCs in TDLNs. Here we use transcriptomic 31 
analysis of stromal populations isolated from LNs to demonstrate that FRCs, 32 
specifically within TDLNs, undergo structural remodeling and transcriptional 33 
modifications, and that these correlate with gross modifications in cellular 34 
 4 
composition and localization prior to the arrival of tumor cells. These 1 
observations imply that aberrant stromal cues impact the downstream 2 




Enlargement of TDLNs is supported by expansion of stromal cells and 2 
FRC network remodeling. 3 
The role of stromal cells within tumor draining lymph nodes (TDLNs) and their 4 
contribution to the evolving microenvironment has yet to be established. 5 
Therefore to study stromal cells during tumor development, prior to the 6 
establishment of LN metastases, we utilized a well-established B16.F10 7 
melanoma model in which individual draining LNs were assessed over a 8 
period of 14 days. Confocal imaging of whole nodes illustrated significant 9 
enlargement of tumor-draining brachial LNs (Fig. 1a and Supplementary Fig. 10 
1a). Quantification of LN cellularity by flow cytometry further confirmed the 11 
expansion of LNs downstream of tumors (Fig. 1b and c) at pre-metastatic 12 
time points. The absence of tumor cells in TDLNs was confirmed by qRT-PCR 13 
of Tyr1 and Dct mRNA expression in total LNs (Supplementary Fig 1b). In 14 
contrast, LNs of PBS-injected control mice (non-draining lymph nodes; 15 
NDLNs) remained at a constant size over the period examined (Fig. 1c). The 16 
observed increases in cellularity were confined specifically to sentinel LNs, as 17 
adjacent, but not primary draining LNs, did not expand (Supplementary Fig. 18 
1ci total LN and stromal cells cii).  19 
To examine stromal cells within TDLNs, populations were identified based on 20 
the differential expression of PDPN and CD31 among CD45- non-21 
hematopoietic cells (gating strategy Fig. 1b). Using this approach, significant 22 
expansion in BECs, LECs and FRCs was recorded over the course of tumor 23 
development specifically within TDLNs (Fig. 1d). Consistent with B16.F10 24 
allografted tumors, TDLNs of tumor-bearing Tyr::CreER,BrafCA,Ptenlox mice, 25 
which develop melanoma after induction of melanocyte-specific BrafV600E 26 
expression and Pten silencing, were also enlarged (Fig. 1e and 27 
Supplementary Fig. 2a). In these animals, tumors developed at multiple 28 
independent sites; primarily the shoulder and lower flank. Quantification of 29 
cellularity in draining inguinal LNs (iLNs) and brachial LNs (braLNs) confirmed 30 
enlargement, which was supported by expansion of all stromal populations 31 
(Fig. 1f and Supplementary Fig. 2a). Proliferation of expanding FRCs was 32 
confirmed by in vivo EdU labeling. Surprisingly, turnover of LECs and BECs 33 
 6 
remained in line with ND counterparts (Supplementary Fig. 2b). Indicative of 1 
a requirement beyond the provision of structural support to an enlarging node, 2 
a significant increase in the ratio of FRCs to whole node cell counts after 11 3 
days was measured (Supplementary Fig. 2c) leading us to examine FRC 4 
network changes after tumor induction in more detail. FRC networks and 5 
conduits remained intact in TDLNs, with collagen I cores surrounded by ER-6 
TR7 matrix and PDPN+ FRCs (Supplementary Fig.3a-c). Skeleton analysis 7 
of FRC network complexity revealed less branches per field of view in FRCs 8 
of TDLNs compared to NDLNs (Fig. 1g), whereas branch length 9 
(Supplementary Fig. 3d) and FRC cell size (data not shown) were 10 
unchanged. Gap analysis demonstrated significant greater distances between 11 
adjacent FRC networks in TDLNs (Fig. 1h), and further evaluation of PDPN 12 
lined conduits using high power Airyscans revealed that conduit thickness as 13 
measured by ellipse area of the central collagen I core was significantly 14 
enlarged in TDLNs (Fig. 1i). Moreover, such detailed end-on scans highlight 15 
changes to the architecture of individual TDLN conduits compared with ND 16 
counterparts (Fig. 1i and Supplementary Fig.3c). Together, the data imply 17 
that conduits of TDLNs enlarge rather than increase in frequency, and hence 18 
increasing FRC numbers might be required to provide cellular coverage to 19 
support the growing conduit diameter.  20 
 21 
Transcriptional profiling identifies alterations in TDLN FRCs  22 
Considering observations of both TDLN enlargement and FRC network 23 
remodeling and frequent reports of immune dysfunction in tumors21-26 we 24 
sought to identify how FRCs of expanding TDLNs adapt to the evolving 25 
microenvironment, and whether these changes ultimately translate to pro-26 
tumor structural and functional modifications in the LN. To do this, FRCs from 27 
LNs at days 4 and 11 post B16.F10 inoculation were freshly sorted and 28 
subjected to whole genome transcriptional profiling. At day 4, tumors were 29 
barely palpable thus this time point was chosen to represent an early stage of 30 
tumor development, where the tumor microenvironment is not yet fully 31 
established and communications with draining lymph nodes are likely at their 32 
earliest stages via resident dermal lymphatic vessels. In contrast, large day 11 33 
 7 
tumors with established stroma and LN connections represent the late stage 1 
of LN transformation. Inter-replicate coefficients of variation confirmed 2 
consistency between samples, with means of 0.036, 0.037, and 0.035 for 3 
NDLN, day 4 (4d) and day 11 (11d) TDLNs respectively. Analysis of the gene 4 
array data revealed distinct transcriptomes between FRCs from TDLNs and 5 
NDLNs. By plotting probe expression level in order of highest change to 6 
lowest change for day 4 (4d), day 11 (11d) and NDLN expression profiles 7 
(Supplementary Fig. 4a-c), and applying a cutoff of probes with a fold 8 
change > ± 1.5, it is clear that significantly large expression changes occur 9 
within TDLNs. We performed statistical analysis on these most significantly 10 
altered probes from both 4d and 11d TDLN arrays resulting in a total of 244 11 
significantly deregulated probes. We initially calculated principal components. 12 
When plotted, eigenvalues of the principal components (Supplementary Fig. 13 
4d) highlight that a majority of variance in the data (88.9% and 4.5% 14 
respectively) is contained within the first two components, and the first two 15 
components for these deregulated probes partition into their respective 16 
sample types (Fig. 2a). Principal component 1 separates NDLN and day 4 17 
TDLN effectively, and principal component 2 separates NDLN and day 11 18 
TDLN probes. Correlation matrix plots of the same probe set reinforced this 19 
relationship (Fig. 2b), showing strong association within all datasets. This was 20 
further confirmed by hierarchical clustering (Fig. 2c) where all three probe 21 
types were clustered into their respective groups (NDLN, 4d TDLN, and 11d 22 
TDLN), and TDLN samples from the two different time points were clustered 23 
closer to each other than to NDLN samples. The heatmap, however, linked to 24 
the hierarchical clusters (Fig. 2c, bottom) reveals that clusters of samples 25 
(NDLN, day 4 TDLN, and day 11 TDLN) exhibit the same pattern of changes 26 
in expression levels within their groups i.e. all NDLN show the same probe 27 
expression changes. These data demonstrate that expression profiles for 4d 28 
TDLNs and 11d TDLNs are distinct and replicable, and implies that FRCs are 29 
undergoing a gradual reprogramming response after exposure to tumor 30 
factors with 4d representing a distinct and transitional state, rather than simply 31 
exhibiting a weaker profile of 11d TDLNs.  32 
 33 
Identification of specific genes and pathways deregulated in TDLN FRCs 34 
 8 
Initially, FRCs from TDLNs after 4 or 11 days of tumor exposure were 1 
compared to ND FRCs using probes exhibiting over 1.5 fold difference and a 2 
p-value below 0.05 (Supplementary Fig. 5a). Differential deregulation of 3 
probe expression between days 4 and 11 highlighted transient increases or 4 
vice versa, which likely represent early activation or repression of FRC 5 
signaling pathways, and either return to control levels by day 11 or continue to 6 
be further up or downregulated. Whilst the expression levels of probes within 7 
the array clearly differ over time, the number of probes with altered expression 8 
values is comparable. 106 probes were downregulated with a fold change 9 
greater than 1.5 at day 4, and 81 at day 11 with an overlap (i.e. probes that 10 
similarly upregulated in both) of 39 (Fig. 3a i), whereas 117 probes were 11 
upregulated at day 4, 131 at day 11 with an overlap of 25 probes (Fig. 3a ii). 12 
Volcano plots illustrate the top deregulated probes between 4d/11d versus ND 13 
and 11d versus 4d as ranked by their expression levels (Fig. 3b). For 14 
example, AQP1 is among the top upregulated genes after 4d (Fig. 3b i), 15 
however, by 11d it returns to baseline expression levels (Fig. 3b iii and 16 
Supplementary Fig. 8a). In contrast, FXYD6, IGH-4, THY1 and PTX3 (Fig. 17 
3b ii) are among the top upregulated genes when comparing 11d and 4d (Fig. 18 
3b iii), indicating that these represent a unique late stage signature. 19 
Clustering the top deregulated genes into functional groups, clear differences 20 
in genes key to cell proliferation, protein metabolism, mitochondrial function, 21 
movement and migration, and junction molecules were observed (Fig. 3c). 22 
Functional annotations were collated using GSEA and ingenuity (IPA) 23 
analysis according to the overlapping deregulation of probes in 4d and 11d 24 
TD from KEGG (GSEA, normalized enrichment score, Supplementary Fig. 25 
5b), canonical pathways (IPA, displayed ordered by z score or P value, 26 
Supplementary Fig. 5c) and from disease and biofunctions (IPA, displayed 27 
ordered by z score or P value, Supplementary Fig. 5d). 28 
 29 
Perturbation of FRC-derived chemokine/cytokine signaling modifies 30 
immune composition of TDLNs  31 
FRCs are an essential source of chemokines and cytokines necessary for 32 
immune homeostasis, leukocyte trafficking and survival within the LN27. Both 33 
GSEA and Ingenuity (IPA) analyses identified these pathways to be 34 
 9 
significantly deregulated in FRCs of TDLNs (Fig. 4a). While signaling 1 
molecules such as LIMK2, KRAS, TGFBR2 and SRC were upregulated, 2 
cytokines and chemokines including IL19, IL7, CCL4 and CCL21 were 3 
downregulated after 4 and 11d. As FRCs provide the bulk of CCL21 and IL72, 4 
8, 12, directly contributing to lymphocyte localization and survival, mRNA levels 5 
were verified in independent sample sets by qRT-PCR confirming significant 6 
downregulation of IL7 and CCL21 mRNA in TDLN FRCs in both tumor models 7 
examined (Fig. 4b). Confocal imaging further confirmed a reduction in CCL21 8 
expression at the protein level (Fig. 4c). Focusing on the B16.F10 model, a 9 
reduction in T cell area and concurrent increase in the B cell follicle size per 10 
node was measured in imaged TDLNs (Supplementary Fig. 6a) and 11 
corresponding reductions in CD3e+ cellularity were confirmed by flow 12 
cytometry (Fig. 4d). Although no change in CD8a+ T cells were measured 13 
(Supplementary Fig. 6b), a significant reduction in the percentage of CD4+ T 14 
cells was observed in TDLNs after 11 days of tumor drainage (Fig. 4e). Within 15 
this population, the percentage of naïve CD4+CD62L+CD44- T cells dropped 16 
(Fig. 4f). This was accompanied by increases in memory (CD62L+CD44+) and 17 
activated (CD62L-CD44+) CD4+ T cells (Fig. 4f) as well as a significant 18 
increase in CD4+FoxP3+ regulatory T cells (Fig. 4g and Supplementary Fig. 19 
6c). Moreover, we observed impaired homing efficiency of CD4+ T cells into 20 
11d TDLNs (Fig. 4h). Considering the observed FRC network remodeling, 21 
altered chemokine profiles and immune composition into account, we 22 
examined the cellular architecture of LNs and observed mislocalization and 23 
disorganization of major immune cell populations in TDLNs. In contrast to 24 
NDLNs where T and B cell zones were clearly delineated (Supplementary 25 
Fig. 6c, left panel), TDLNs exhibited integration of the 2 populations with loss 26 
of delineation between T/B cell borders (Supplementary Fig. 6d right panel, 27 
and Fig. 4i). A transitional stage was observed in 4d TDLNs (Supplementary 28 
Fig. 6c middle panel). Furthermore, in TDLNs, B cells were frequently 29 
clustered around high endothelial venules (HEVs, Fig. 4j i, quantified in Fig. 30 
4j ii). As no differences in B cell homing capacity were measured between ND 31 
and TDLNs (Fig. 4k), this, together with FRC-derived cytokine changes would 32 
imply that in TDLNs, once exited HEVs, B cells are not able to sense the 33 
appropriate cues responsible for directing them to the B cell follicle. Moreover, 34 
 10 
staining with EdU indicated a reduced proliferation of T cells and B cell 1 
compartments from TDLNs (Supplementary Fig. 6e and f). Beyond CCL21 2 
and IL7, the gene array also highlighted other factors deregulated in FRCs of 3 
TDLNs. These included CXCL14, chemotactic to monocytes and DCs; 4 
CCL25, chemotactic to DCs; and CCL7, chemotactic to monocytes; all of 5 
which were upregulated at day 11. Consistent with gene array trends, and 6 
following a transient dip at day 4, CD11c+ dendritic cells (DCs) and CD11b+ 7 
Macrophages (MΦ, Supplementary Fig. 7a) significantly increased in 8 
numbers in 11d TDLNs (Supplementary Fig. 7b and c). 9 
 10 
FRCs of TDLNs are more activated  11 
Disruption of ECM homeostasis and “cancer-associated fibrosis” is commonly 12 
observed at the primary tumor28, and is mediated by hyper-activated 13 
fibroblasts (cancer-associated fibroblasts, CAFs) within the local 14 
microenvironment29. Therefore, adaptation of the pre-metastatic lymph node, 15 
reliant of fibroblast remodeling is also likely to be reminiscent of fibrosis30, 31. 16 
Microarray data highlighted elevated expression levels of genes encoding 17 
typical fibroblast activation markers including podoplanin, fibronectin, CD248, 18 
α-smooth muscle actin, FSP1, vimentin, myosin light chains and collagens 19 
(Fig. 5a) indicating the heightened activation status of FRCs in nodes draining 20 
tumors. Levels of PDPN, FSP1, THY1 and CD248 were further verified on 21 
independent data sets by qRT-PCR (Fig. 5b and Supplementary Fig. 7d) 22 
and PDPN at the protein level by flow cytometry (Fig. 5c). Although not 23 
significant, trends for PDPN, FSP1 and THY1 in the genetic model largely 24 
supported that of the B16 at the mRNA level, however, at the protein level 25 
podoplanin was significantly increased in both models. Moreover, flow 26 
cytometry indicated that tumor draining FRCs increase in granularity, which is 27 
indicative of increased internal complexity and corresponding increased 28 
activation status (Fig. 5d). To investigate the activation status further, cultured 29 
FRCs treated with tumor conditioned medium (TCM) obtained from B16.F10 30 
cells for 7 days were compared to control conditioned medium (CCM) treated 31 
cells. In vitro, PDPN was upregulated at both mRNA (Fig. 5e) and protein 32 
levels (Fig. 5f), and TCM treatment enhanced the capacity of FRCs to 33 
contract collagen gels (Fig. 5g).  34 
 11 
 1 
TDLN conduits are more permissive for large molecular weight solute 2 
transport 3 
Profiling of TDLN FRCs also hinted at previously undocumented behavior, in 4 
particular, a significant number of channels/ion transporters are deregulated in 5 
either 4d or 11d TDLNs (Fig. 6a). For example, Aquaporin 1 (AQP1) is highly 6 
upregulated in FRCs of 4d TDLNs, before subsequent downregulation by 11d 7 
(verified by qRT-PCR in Supplementary Fig. 8a). In vitro, cultured FRC 8 
monolayers exhibited a less selective barrier, allowing greater trans-9 
monolayer transport of 500 kDa dextran following exposure to TCM (Fig. 6b). 10 
To investigate if changes to levels of these channels and transporters can 11 
impact fluid transport through the conduit system in vivo, dextran transport 12 
studies were performed and quantified. The capacity of conjugated dextran of 13 
different molecular weights to transit into the normally size-restricted conduits 14 
was analyzed and measured. In both resting and TDLNs, 10 kDa dextran 15 
freely entered into FRC lined conduits, but in contrast to resting nodes, 70 16 
kDa dextran permeated further into paracortical area of 11d TDLNs (Fig. 6c 17 
and d), where it was restricted to the FRC lined conduits (Fig. 6e). Taken 18 
together with earlier data showing larger diameter conduits at 11d (Fig. 1g), 19 
altered transporter repertoires point to a perturbation of conduit capacity, 20 
whereby in TDLNs conduits are more permissive for fluid to enter and transit, 21 
potentially enabling greater penetration of soluble tumor-derived factors to 22 
deeper areas of the LN. As a result of the altered environment of TDLNs, 23 
significant changes in cell assembly machinery would be expected to underlie 24 
the restructuring and enlargement of the FRCs, as would the need for 25 
interaction with associated matrix proteins essential to the conduit. The 26 
observation of thickened collagen cores but reduced branches implies that 27 
additional FRCs go to support the increased diameter of the conduit. In doing 28 
so, FRCs will form contacts with a larger number of neighbors, and encounter 29 
a greater area of their neighboring cells. As predicted, network analysis (Fig. 30 
6f, with interaction networks shown in Supplementary Fig. 8b), highlights 31 
four significantly relevant probe groups heavily involved in cell structure, 32 
shape and extracellular matrix. Such analyses link probe sets into functionally 33 
and spatially linked networks, highlighting families of genes that are both 34 
 12 
significantly deregulated and involved in the same biological pathways, 1 
expressed together, or have physical interactions. A schematic model shown 2 
in Fig. 6g illustrates the conduit profile in a resting state (ND) and at an 3 
advanced pre-metastatic stage (TDLN day 11). Gene array expression data 4 
for day 4 suggests that cells proliferate and conduits begin to reorganize, 5 
potentially driven by increased drainage from the tumor or exposure to tumor-6 
derived factors. At the same time, deregulation of ion channels and 7 
aquaporins result in changes to the cells capacity to deal with fluid and the 8 
immunological profile of the cell changes. By day 11, imaging studies, 9 
combined with gene expression analysis show that a new altered state is 10 
reached, characterized by transcriptional signatures and structural 11 
adaptations that drive modulation of a) scaffolding proteins involved in the 12 
cytoskeleton, cell junctions and extracellular matrix remodelling, b) cytokines 13 
(CCL21 and IL7) and other biochemical cues, and c) conduit integrity, 14 




Lymph nodes function as a major immunological hub, essential for immune 3 
homeostasis and generation of appropriate immune responses, yet LNs are 4 
also the first site of metastasis for many cancers that manage to avoid 5 
immune-mediated clearance. It is increasingly accepted that LNs receive and 6 
respond to tumor-derived signals generating a pro-tumor niche, but it remains 7 
unclear as to how these responses manifest and who in the LN drives them. 8 
The stromal populations of the LN not only provide structural support but are 9 
essential to its maintenance and physiological function1-3, 6, 8-14, 32-36. While 10 
studies have shown that tumor-derived VEGF and VEGF-C contribute to LN 11 
lymphangiogenesis and vascular reorganization37-39, the fibroblasts of the LN, 12 
FRCs, and the conduit network they form have not been thoroughly 13 
investigated in the context of the tumor and subsequent modulation of LN 14 
behavior. Here we describe that expansion, remodeling and transcriptional 15 
reprogramming of FRCs occurs in TDLNs. This in turn impacts FRC-driven 16 
chemokine signaling, trafficking events, immune localization and transport, all 17 
of which have the potential to contribute to impaired lymph node function, that 18 
in the context of a tumor may provide a pro-tumor environment. 19 
 20 
We demonstrate that TDLNs enlarge, consistent with previous studies37, 39, 40. 21 
Integral to this enlargement is structural reorganization of the node supported 22 
by expansion and adaptation of the stromal compartments. In particular, we 23 
observed that the FRCs not only increased in number, but the resulting 24 
network exhibited fewer FRC branches that were further apart, and conduit 25 
diameters were significantly greater. To understand the potential ramifications 26 
of such changes within the stromal compartment we then analyzed 27 
transcriptomes of FRCs isolated from resting and tumor draining LNs. This 28 
analysis revealed striking transcriptional reprogramming events restricted to 29 
the node immediately downstream of a tumor, and identified a transitional 30 
process with early response genes and deregulation of key pathways 31 
including fibrosis, chemokine and cytokine signaling, immune cell migration, 32 
activation and trafficking. 33 
 14 
Key to LN function, FRC-derived CCL21 and IL-7 were deregulated. 1 
Significant downregulation was verified in two independent murine models of 2 
melanoma. Decreased expression of both can contribute to abnormal immune 3 
cell homing, localization and survival. It has been previously reported that 4 
TDLNs exhibit reduced CCL2141, 42. Consistent with these findings we 5 
observed gross architectural aberrations, with loss of the clear demarcation 6 
between B and T cells, T cells frequently located within B cell zones, and 7 
reduced T cell area. These features phenocopy plt/plt mice, where 8 
spontaneous loss of LN-specific CCL19 and CCL21 isoforms translate to 9 
fewer T cells and impaired immune responses2, 12, 34, 43. Moreover, CCL21 10 
produced by FRCs surrounding high endothelial venules (HEVs) is essential 11 
for egress of B cells and T cells from the circulation towards their respective 12 
compartments. As observed in TDLNs, B cells displayed no impairment in LN 13 
homing, accumulated around HEVs indicating disruption of their normal 14 
guidance cues. 15 
Our results also draw parallels with other pathological states such as 16 
infection, where reduced nodal CCL21 underpins the aberrant homing and 17 
mislocalization of key immune populations required for immune evasion by 18 
Salmonella or virus particles14, 35, 44. It should be noted however, that 19 
pathogen-related inflammation was not underlying our observations. Firstly, 20 
stromal modifications were consistent in two independent melanoma models, 21 
one of which is genetically driven rather than allografted. Secondly, a 22 
comparison of our array with data from Malhotra et al., in which responses of 23 
lymph node stroma to LPS-mediated inflammation were characterized27, 24 
shows that the response of the FRCs downstream of a tumor is tumor-25 
dependent. In particular, key factors such as CCL21 and IL7 were inversely 26 
regulated between the two pathological settings (data not shown). 27 
Furthermore, upregulation of several other chemotactic factors were recorded 28 
indicating changes to other immune populations in the LN; CXCL14, 29 
chemotactic to monocytes and DCs, CCL25, chemotactic to DCs, and CCL7, 30 
chemotactic to monocytes. Additionally, CCL4 also known as MIP-1β was 31 
found to be downregulated. CCL4-responsive antigen-naïve CD8 T cells have 32 
been reported to chemotact to sites rich in stimulated DCs, which is implicated 33 
 15 
in optimal activation of CD8+ T cells and long term memory45. Since FRCs 1 
have been shown to be the source of CCL411 in the LN, a downregulation in 2 
TDLNs may result in a reduction of this T cell population. Beyond the 3 
disruption of immune compartmentalization, we also present evidence to 4 
implicate FRC transcriptional modulation in the altered immune composition of 5 
TDLNs. Within draining nodes, we observed fewer naïve CD4+ T cells and 6 
accumulation of Tregs consistent with previous studies correlating their 7 
presence with immune suppression and disease progression46. We detected 8 
enlarged B cell follicles within TDLNs, and although the activation status or 9 
subtypes of the B cells occupying TDLNs remains to be determined, recent 10 
reports have demonstrated that B cells do indeed accumulate in TDLNs47, 11 
and that these may function as regulatory B cells48 adding a further dimension 12 
to the local immune suppressive environment. 13 
Transcripts of TDLN FRCs also indicated the acquisition of a more activated 14 
status evident from upregulation of Thy1, podoplanin, FSP1, CD248, vimentin, 15 
collagens, fibronectin, α smooth muscle actin, and the capacity to contract 16 
collagen gels more efficiently upon receipt of tumor conditioned media, 17 
consistent with previous work49, 50. This signature in particular is reminiscent 18 
of fibroblasts found within the tumor microenvironment, and that also possess 19 
immune suppressive attributes51-55, leading us to speculate that in LNs 20 
downstream of tumors, FRCs adopt a more CAF-like state to provide a 21 
supportive niche28, 30, 31.  22 
 23 
Within TDLNs, wider conduits and enhanced collagen deposition point to 24 
increased stiffness of the node40, but the remodeling of the collagen core may 25 
also contribute to the size exclusion properties of the conduits5, 6, that in 26 
TDLNs was disrupted with large MW dextran reaching deeper into the conduit 27 
network than in resting nodes. This, combined with deregulated junction 28 
properties and protein pores of the FRCs lining these channels, suggests an 29 
altered integrity of the conduit network. These changes have the potential to 30 
lead to rapid, but poorly controlled delivery of tumor-derived factors, debris 31 
and antigen to the deeper areas of the LN upsetting the functional status quo. 32 
Moreover, the process of lymphangiogenesis both at primary tumors and 33 
 16 
connected LNs enhances the drainage capacity, and consequently these 1 
stromal populations experience raised fluid flux and shear stresses. 2 
Mechanical cues such as these rather than chemical, tumor-derived signals 3 
(data not shown) may also act as a stimulus for FRC proliferation56-59 or 4 
synergize to drive the transcriptional reprogramming. We have not excluded 5 
this in the present study, but this avenue warrants more in depth investigation 6 
using in vitro studies in which the effects of biophysical stimuli i.e. flow can be 7 
isolated. 8 
 9 
In summary, using functional assays and comparative transcriptome analysis 10 
of FRCs in resting and TDLNs in multiple tumor models, we demonstrate that 11 
FRCs immediately downstream of tumors acquire unique transcriptional 12 
programs. Together with structural remodeling, these deregulated pathways 13 
and adapted FRC traits contribute to modified immune composition and 14 
aberrant localization that may ultimately translate to a more suppressive, pro-15 
tumor environment. 16 
 17 
METHODS 18 
Methods and any associated references are available in the supplementary 19 
information of the paper. 20 
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Figure legends 1 
Figure 1: LN expansion and FRC network remodeling in TDLNs. (a) 2 
Representative confocal images of ND (left) and 11d TD (right) brachial LNs 3 
showing stromal cell populations and the increased size of TDLNs. (b) Flow 4 
cytometry gating strategy for isolation of stromal cells from ND (top) and 11d 5 
TD (bottom) LNs. Stromal subtypes: FRC, PDPN+CD31-; LEC, PDPN+CD31+; 6 
BEC, PDPN-CD31+. Numbers in boxes represent percentages of parent 7 
population in gate. (c and d) Expansion of TD (red) compared to ND (PBS 8 
control, cyan) LNs over a time course of 14 days measured by flow cytometry. 9 
Total LN cells (c), BECs, LECs, and FRCs (d) were quantified. Quantification 10 
of total LN cells (e) and stromal cells (f) of TDLNs and NDLNs measured by 11 
flow cytometry in shoulder B16.F10 or induced Tyr::CreER,BrafCA,Ptenlox 12 
tumors on either the shoulder or lower flank. For shoulder tumors the brachial 13 
LN (braLN) and for flank tumors the inguinal LN (iLN) were identified to be the 14 
primary draining LNs. (g) Skeleton analysis of collagen I networks in T cell 15 
areas determined the number of conduit branches per Field Of View (FOV) in 16 
ND and TDLNs. (h) Gap analysis of collagen I networks determined the 17 
distance between conduit branches in ND and TDLNs. (i) Confocal Airyscans 18 
of conduit end and side views stained for PDPN, collagen I and ERTR7 (left 19 
panel). Conduit thickness measured by 0.1 µm z-stacks of the conduit 20 
collagen I core rotated to display ellipse area of cross section for ND and 21 
TDLNs (right panel). (c and d) Data are representative of two independent 22 
experiments with each 2 (Ctrl) and 3 (Tumor) LNs from independent mice per 23 
replicate. (e and f) Data are representative of 2 independent experiments with 24 
each 3 (ND) and 5 (TD) LNs (B16.F10) and 3/4 (iND) and 2 (iTD, braND, 25 
braTD) (Tyr::CreER,BrafCA,Ptenlox) from independent mice per replicate. (g 26 
and h) Data are from 3-6 individual LNs from independent mice with 3 FOV 27 
analyzed per LN, (i) 3-4 individual LNs from different mice with 5 conduits per 28 
LN imaged and 3 measurements per conduit performed in shortest and 29 
longest axis. Data points indicate the mean ± s.e.m. *P <0.05, **P <0.01 and 30 
***P <0.001. For time courses, data were subjected to two-way ANOVA, 31 
followed by post hoc analysis. When two groups were compared, a two-tailed 32 
 24 
unpaired Student’s t-test was applied. Scale bars (a) 200 µm, (g and h) 50 1 
µm. 2 
 3 
Figure 2: Statistical analysis of microarray results. (a) Principle Component 4 
Analysis of samples from ND, 4d TD, and 11d TD LNs. Analysis was 5 
performed on the most significantly deregulated samples (FC > ± 1.5), and 6 
those with a p value of greater than 0.05, leaving a total of 244 probes. The 7 
top two most significant eigenvectors are illustrated, accounting for 93.4% of 8 
the total variability between samples. Expression data was log2 transformed 9 
and normalized by row before principal component analysis was performed. 10 
(b) Heatmap of coefficients of correlation for most significantly deregulated 11 
probes (the same dataset as used in part a). Red indicates the highest 12 
correlation. (c) Hierarchical clustering analysis of all samples with heatmap of 13 
the top deregulated probes. All analyses were performed on probes with an 14 
expression fold change of over 1.5 and a P value <0.05. Each data point 15 
representing transcriptomes of FRCs of 2 brachial LNs, pooled per mouse. 16 
 17 
Figure 3: Identification of specific genes and pathways deregulated in TDLN 18 
FRCs. (a) Venn diagrams displaying overlap between significantly 19 
downregulated (i), and significantly upregulated (ii) probes in ND, 4d TD, and 20 
11d TD samples. (b) Significantly deregulated probes represented on volcano 21 
plots for 4d TD vs. ND (i), 11d TD vs. ND (ii), and 11d TD vs. 4d TD (iii). 22 
Probes displayed with the most significantly deregulated (FC >± 1.5) 23 
represented as blue (downregulated) or red (upregulated). (c) Heatmaps of 24 
key pathways involving the top deregulated genes with a FC of over 1.5 and a 25 
P<0.05 compared between 4d TD vs. ND and 11d TD vs. ND. Functional 26 
groups were assigned with GSEA and IPA.  27 
 28 
Figure 4: Perturbation in LN critical chemokine/cytokine signaling pathways 29 
correlates with changes in immune cell composition and localization. (a) 30 
Heatmap of significantly deregulated probes (P<0.05) falling into the category 31 
of cytokine and chemokine signaling molecules. Pathway analyses were 32 
performed with GSEA and IPA. (b) mRNA expression levels of IL7 and 33 
CCL21 measured by qRT-PCR in an independent FRC sample set from 34 
 25 
B16.F10 ND, 4d TD and 11d TD LNs, and ND and TD LNs obtained from 1 
Tyr::CreER,BrafCA,Ptenlox tumor-bearing mice. (c) Representative confocal 2 
images of LN paracortical areas of ND (top panel) and 11d TD (bottom panel) 3 
LNs stained for PDPN (green), ERTR7 (blue) and CCL21 (red). (d) Flow 4 
cytometric quantification of T cells (CD45+CD3e+) as percentage of singlets 5 
within ND and 11d TD (B16.F10) LNs. (e) Quantification of CD4+ T cells 6 
(CD45+CD3e+CD4+) in ND and 11d TD (B16.F10) LNs. (f) Quantification of 7 
CD4+ T cell populations; naïve CD62L+CD44-, memory CD62L+CD44+ and 8 
activated CD62L-CD44+. (g) Flow cytometric measurement of regulatory T 9 
cells (CD45+CD3e+CD4+FoxP3+). (h) LN homing assay: Splenocytes were 10 
isolated from GFP+ C57bl/6 mice and injected into wt mice. After 18h LNs 11 
were isolated and immune cell contents were analyzed by flow cytometry. 12 
Quantification of homed CD4+ T cells is expressed as ratio of 13 
CD4+GFP+:GFP+ within ND and 11d TD (B16.F10) LNs. (i) Representative 14 
confocal images of B cell follicles of ND and 11d TDLNs (B16.F10) stained for 15 
CD3e (green), CD45R (red) and Collagen I (blue). (j) Representative confocal 16 
images (i) of ND and 11d TD LNs (B16.F10) stained for CD3e (green) CD45R 17 
(red) and PNAd (blue). Quantification of B cell clustered HEVs on LN sections 18 
(ii). (k) LN homing assay as described in (h): Flow cytometric quantification of 19 
CD45R+ expressed as ratio CD45R+GFP+:GFP+ within ND and 11d TD LNs 20 
(B16.F10). Each data point represents whole transcriptome amplified (WTA) 21 
mRNA samples of brachial LNs pooled per mouse, with 3 mice per condition 22 
and technical duplicates of WTA (B16.F10) and with 5 mice (ND) and 7 mice 23 
(TD) (Tyr::CreER,BrafCA,Ptenlox) (b). Data collected from 5-6 individual ND or 24 
TD LNs from different mice (d). Data representative of 8-10 individual LNs per 25 
condition from two independent experiments (e and f). Data are from 6 ND 26 
and 9 TD LNs from different mice (g). Data collected from two independent 27 
experiments with each 4 (ND) and 3 (TD) LNs (h and k). Data representative 28 
of 6 (ND) and 5 (TD) LNs obtained from independent mice (jii). Data points 29 
indicate the mean ± s.e.m. *P <0.05, **P <0.01 and ***P <0.001. For 30 
comparisons of three or more groups, data were subjected to one-way 31 
ANOVA, followed by post hoc analysis. When two groups were compared, a 32 
two-tailed unpaired Student’s t-test was applied. Scales bars (c and j) 50 µm, 33 
(i) 51 µm (ND) and 38 µm (TD). 34 
 26 
 1 
Figure 5: FRCs in TDLNs become more activated. (a) Heatmap of 2 
significantly deregulated probes (P<0.05) falling into the category of fibroblast 3 
activation status. (b) mRNA expression levels of PDPN, FSP1 and THY1 4 
measured by qRT-PCR in an independent FRC sample set from ND (cyan) 4d 5 
TD (black) and 11d TD (red) LNs from B16.F10, and ND (cyan) and TD (red) 6 
LNs obtained from the Tyr::CreER,BrafCA,Ptenlox model. (c) Flow cytometric 7 
analysis of PDPN surface expression as measured by relative mean 8 
fluorescence intensity of the geometric mean in FRCs isolated from B16.F10 9 
ND, 4d and 11d TDLNs, or ND and TDLNs from the Tyr::CreER,BrafCA,Ptenlox 10 
mice. (di) Representative scatter profile of alive FRCs from ND (left) and 11d 11 
TDLN (right) and (dii) geometric mean of the side scatter of FRCs sorted from 12 
B16.F10 ND (cyan), 4d TD (black) and 11d TD (red) LNs, or ND (cyan) and 13 
TD (red) LNs from Tyr::CreER,BrafCA,Ptenlox mice. (e) mRNA and (f) protein 14 
expression of PDPN by in vitro cultured FRCs treated with control conditioned 15 
medium (CCM) or tumor conditioned medium (TCM) for 7 days as measured 16 
by qRT-PCR or flow cytometry. (g) Comparison of the collagen gel contractile 17 
activity of in vitro FRCs pretreated with CCM or TCM. Each data point 18 
represents WTA mRNA samples of brachial LNs pooled per mouse, with 3 19 
mice per condition and technical duplicates of WTA (B16.F10) and with 5 20 
mice (ND) and 7 mice (TD) (Tyr::CreEr,BrafCA,Ptenlox) LNs.  (b). Data are from 21 
4-7 (B16.F10) or 4-12 (Tyr::CreER,BrafCA,Ptenlox) individual LNs taken from 22 
different mice (c and d). Data are representative of three independent 23 
experiments (e - g) performed in triplicate per condition. Data points indicate 24 
the mean ± s.e.m. *P <0.05, **P <0.01 and ***P <0.001. For comparisons of 25 
three or more groups, data were subjected to one-way ANOVA followed by 26 
post hoc analysis. When two groups were compared, a two-tailed unpaired 27 
Student’s t-test was applied 28 
 29 
Figure 6: Modified transporter repertoires within TDLN FRCs translate to 30 
altered solute transport throughout the conduit system of the node. (a) 31 
Heatmap for significantly (P<0.05) deregulated probes involved in ion/solute 32 
conduction or membrane permeability. (b) In vitro measurement of relative 33 
permeability of 10 70 and 500 kDa dextran transport through an FRC 34 
 27 
monolayer pretreated for 7 days with CCM or TCM and measured after 22 h. 1 
(c) Filling of the conduit network in ND and 11d TD LNs 10 min after 2 
subcutaneous injection of Texas Red-labeled 10 kDa dextran and biotin-3 
labeled 70 kDa dextran. Quantification of fluorescence signals of 70kDa 4 
dextran and ERTR7 per paracortical area displayed as area fraction (ci and 5 
cii). (d) Quantification of 70 kDa dextran as relative fluorescence intensity (FI) 6 
per area and representative high-magnification micrograph of the paracortical 7 
region from ND and 11d TDLNs counterstained with PDPN. Each channel is 8 
gray scaled (e) Close up of dextran filled conduit from a 11d TDLN, staining 9 
for 70 kDa dextran (magenta) within a PDPN+ FRC (green) lined conduit. (f) 10 
Network analysis of the top deregulated probes within gene arrays for 11d 11 
TDLN samples. Top networks calculated with the MANIA algorithm are shown 12 
with heatmaps of the probes for each time point. Sets of probes are related 13 
through either function, regulation, or physical space. (g) Schematic of the 14 
proposed changes in FRC conduits. In response to tumor factors ND (left) 15 
FRCs proliferate leading to an increase in the size of the conduit by 11d 16 
(right), and matrix deposition manifesting as increased diameter of the 17 
collagen core. Subsequent to this there is an increase in the amount of 18 
solute/ion transporters expressed within the cells leading to a potential 19 
increase in fluid movement within the conduits. By 11d TD, the increased 20 
expression of solute/ion channels leads to a potential increase in the ability for 21 
fluid to pass through the conduit. The concurrent upregulation of extracellular 22 
matrix components and altered cell-cell interactions indicate a potential 23 
thickening of the matrix of the conduit core. Furthermore, two important FRC 24 
factors, CCL21 and IL7 are downregulated over time leading to changes in 25 
immune cell localization and composition. Data are representative of two 26 
independent experiments (b) performed in five replicates per condition. Data 27 
are from 4 (ND) or 3 (TD) (B16.F10) individual LNs taken from different mice 28 
(c and d). Data points indicate the mean ± s.e.m. *P <0.05, **P <0.01 and 29 
***P <0.001. For comparisons, a two-tailed unpaired Student’s t-test was 30 
applied. Scale bars (d) 50 µm (e) 3.4 µm. 31 
 32 
 33 
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